Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids

The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.

Inclusion Criteria:

• Patient greater than or equal to 18 years of age,
• non-smokers,
• diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
• stable use of Beta agonist
• daily use of inhaled steroids for one year

Exclusion Criteria:

• Patients with other significant diseases other than asthma, requiring oxygen,
• intubated within 5 years,
• asthma exacerbation within 6 weeks of trial,
• use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
• participating in another interventional trial